
Lundbeck appoints two new R&D vice presidents
pharmafile | November 1, 2011 | Appointment | Research and Development | Lundbeck, R&D
Lundbeck has appointed Jens Peter Balling and Iman Barilero as vice presidents of its research and development organisation.
The new appointments have been made following the consolidation of Lundbeck’s R&D activities into one unit.
One result of this consolidation is the creation of a new unit for regulatory product support, patient safety and quality assurance of clinical research and Jens Peter Balling has been appointed as vice president of this new unit.
Jens Peter Balling joined Lundbeck in 2006 as divisional director of global pharmacovigilance.
He has many years of drug safety experience from the Danish pharma industry, where he previously worked for Novo Nordisk and Nycomed.
Iman Barilero will be responsible for increasing Lundbeck’s strategic efforts to build and maintain relationships with national and international regulators, and will have a particular focus on supporting Lundbeck’s many development projects.
Iman Barilero joined Lundbeck in 2007, when she started as divisional director of regulatory development, strategy and policy.
She has strong international experience from several years at Roche and Johnson & Johnson.
Anders Gersel Pedersen, Lundbeck’s executive vice president of R&D, said: “The appointments of Jens Peter Balling and Iman Barilero reflect our efforts to build a strong and competent research and development organisation that enables us to continue to deliver results as we invest in the future.”
Related Content

ANGLE’s Parsortix system used in new cancer biology research
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour …

Moderna expands use of AI-ready R&D platform
Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader …

Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases
Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part …






